Log In
Print
BCIQ
Print
Print this Print this
 

memantine ER/donepezil (Namzaric) (ADS-8704, MDX-8704)

Also known as: Arimenda

  Manage Alerts
Collapse Summary General Information
Company Adamas Pharmaceuticals Inc.
DescriptionOnce-daily, fixed-dose combination of memantine ER, a NMDA receptor antagonist, and donepezil, an acetylcholinesterase (AChE) inhibitor
Molecular Target NMDA receptor ; Acetylcholinesterase (AChE)
Mechanism of ActionAcetylcholinesterase (AChE) inhibitor; NMDA receptor antagonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat moderate to severe Alzheimer's dementia
Regulatory Designation

Partner

Allergan plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$160.0M

$65.0M

$95.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today